MCID: LVR013
MIFTS: 68

Liver Disease

Categories: Blood diseases, Endocrine diseases, Gastrointestinal diseases, Genetic diseases, Liver diseases, Metabolic diseases, Nephrological diseases, Rare diseases

Aliases & Classifications for Liver Disease

MalaCards integrated aliases for Liver Disease:

Name: Liver Disease 12 15 37 17
Liver Diseases 54 42 43 71
Abnormality of the Liver 29 6
Liver Dysfunction 54 71
Liver Failure 54 71
Disorder of Liver 12
Hepatic Disorder 12
Hepatic Failure 29
Hepatic Disease 15

Classifications:



External Ids:

Disease Ontology 12 DOID:409
ICD9CM 34 573.9
MeSH 43 D008107
NCIt 49 C3196
SNOMED-CT 67 62857009
UMLS 71 C0023895 C0085605 C0086565

Summaries for Liver Disease

MedlinePlus : 42 Your liver is the largest organ inside your body. It helps your body digest food, store energy, and remove poisons. There are many kinds of liver diseases: Diseases caused by viruses, such as hepatitis A, hepatitis B, and hepatitis C Diseases caused by drugs, poisons, or too much alcohol. Examples include fatty liver disease and cirrhosis. Liver cancer Inherited diseases, such as hemochromatosis and Wilson disease Symptoms of liver disease can vary, but they often include swelling of the abdomen and legs, bruising easily, changes in the color of your stool and urine, and jaundice, or yellowing of the skin and eyes. Sometimes there are no symptoms. Tests such as imaging tests and liver function tests can check for liver damage and help to diagnose liver diseases.

MalaCards based summary : Liver Disease, also known as liver diseases, is related to fatty liver disease and polycystic liver disease, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Liver Disease is MEG3 (Maternally Expressed 3), and among its related pathways/superpathways are Metabolism and Folate Metabolism. The drugs Methylprednisolone and Methylprednisolone hemisuccinate have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and kidney, and related phenotypes are homeostasis/metabolism and liver/biliary system

Wikipedia : 74 Liver disease (also called hepatic disease) is a type of damage to or disease of the liver. Whenever the... more...

Related Diseases for Liver Disease

Diseases in the Liver Disease family:

Liver Failure, Infantile, Transient Infantile Liver Failure Syndrome 1
Infantile Liver Failure Syndrome 2 Infantile Liver Failure Syndrome 3
Acute Liver Failure

Diseases related to Liver Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1904)
# Related Disease Score Top Affiliating Genes
1 fatty liver disease 35.5 PNPLA3 INS GPT GGT1 CYP2E1 ALB
2 polycystic liver disease 35.4 SEC63 PRKCSH PKHD1 PKD1 LRP5 GGT1
3 non-alcoholic fatty liver disease 35.3 PNPLA3 INS GPT GGT1 CYP2E1 ALB
4 fatty liver disease, nonalcoholic 1 35.3 PNPLA3 INS GPT GGT1 ADIPOQ
5 polycystic liver disease 1 with or without kidney cysts 35.2 SEC63 PRKCSH PKHD1 PKD1 LRP5
6 polycystic kidney disease 4 with or without polycystic liver disease 35.1 SEC63 PRKCSH PKHD1 PKD1 GANAB
7 polycystic kidney disease 2 with or without polycystic liver disease 35.0 SEC63 PRKCSH PKHD1 PKD1
8 polycystic kidney disease 1 with or without polycystic liver disease 35.0 SEC63 PRKCSH PKHD1 PKD1
9 alcoholic hepatitis 34.4 PNPLA3 GPT GGT1 F2 CYP2E1 ALB
10 non-alcoholic steatohepatitis 34.4 INS GPT GGT1 ADIPOQ
11 primary biliary cirrhosis 33.9 GPT GGT1 F2 DLAT ALB ABCB11
12 alpha-1-antitrypsin deficiency 33.8 SERPINA1 GPT F2 ALB
13 wilson disease 33.6 PNPLA3 GPT F2 ALB
14 bile acid synthesis defect, congenital, 1 33.6 HSD3B7 GPT GGT1 ALB
15 cholangitis, primary sclerosing 33.5 GPT GGT1 F2 DLAT ALB ABCB11
16 alcohol use disorder 33.5 GPT GGT1 CYP2E1 ALB
17 hemochromatosis, type 1 33.4 SERPINA1 INS GPT ALB
18 sclerosing cholangitis 33.3 GPT GGT1 F2 ALB ABCB11
19 acute liver failure 33.3 GPT F2 ALB
20 hepatic vascular disease 33.3 PKHD1 GPT GGT1 F2 ALB
21 hepatic encephalopathy 33.2 GPT F2 ALB
22 hepatorenal syndrome 33.2 GPT F2 ALB
23 autoimmune hepatitis 33.1 GPT GGT1 F2 DLAT ALB
24 drug-induced hepatitis 33.0 GPT CYP2E1 ALB
25 congenital hepatic fibrosis 33.0 PKHD1 PKD1
26 liver cirrhosis 33.0 SERPINA1 MEG3 GPT GGT1 FAH F2
27 viral hepatitis 32.7 SERPINA1 PNPLA3 INS GPT GGT1 F2
28 alcoholic liver cirrhosis 32.7 PNPLA3 INS GPT F2 CYP2E1 ALB
29 idiopathic edema 32.7 INS ADIPOQ
30 cholestasis 32.6 SERPINA1 HSD3B7 GPT GGT1 F2 ALB
31 portal hypertension 32.6 PNPLA3 PKHD1 INS GPT F2 ALB
32 cholangitis 32.5 GPT GGT1 F2 DLAT ALB ABCB11
33 hepatic coma 32.4 GPT F2 ALB
34 hepatitis b 32.2 GPT GGT1 F2 ALB
35 hepatitis a 32.2 SERPINA1 INS GPT GGT1 F2 ALB
36 esophageal varix 32.1 SERPINA1 GPT GGT1 F2 ALB
37 polycystic kidney disease 32.1 PRKCSH PKHD1 PKD1 LRP5 GANAB ALB
38 kidney disease 32.1 PKHD1 PKD1 LRP5 INS GANAB ALB
39 granulomatous hepatitis 32.1 GPT ALB
40 biliary atresia 32.1 GPT GGT1 F2 ALB ABCB11
41 body mass index quantitative trait locus 11 31.9 PNPLA3 INS GPT GGT1 CYP2E1 ALB
42 autosomal dominant polycystic kidney disease 31.9 PKHD1 PKD1 LRP5 INS GANAB ALB
43 leptin deficiency or dysfunction 31.9 PNPLA3 INS GPT ALB ADIPOQ
44 glucose intolerance 31.9 INS GPT ALB ADIPOQ
45 obstructive jaundice 31.8 GPT GGT1 F2 ALB
46 bilirubin metabolic disorder 31.8 GPT GGT1 F2 ALB ABCB11
47 sleep apnea 31.8 INS GPT ALB ADIPOQ
48 hepatitis e 31.8 GPT GGT1 F2 ALB
49 hyperuricemia 31.8 INS GPT GGT1 ALB
50 hypothyroidism 31.8 INS GPT F2 ALB ADIPOQ

Comorbidity relations with Liver Disease via Phenotypic Disease Network (PDN):


Active Peptic Ulcer Disease Acute Cystitis
Acute Pancreatitis Deficiency Anemia
Familial Atrial Fibrillation Heart Disease
Hepatic Encephalopathy Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Liver Disease:



Diseases related to Liver Disease

Symptoms & Phenotypes for Liver Disease

UMLS symptoms related to Liver Disease:


nausea and vomiting, constipation, abdominal pain, diarrhea, hepatosplenomegaly, icterus, dyspepsia, heartburn, gastrointestinal gas, digestive system symptom, liver tender, abnormal bruising

MGI Mouse Phenotypes related to Liver Disease:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.1 ABCB11 ADIPOQ ALB CYP2E1 F2 FAH
2 liver/biliary system MP:0005370 9.97 ABCB11 ADIPOQ ALB CYP2E1 FAH HSD3B7
3 mortality/aging MP:0010768 9.83 ABCB11 ADIPOQ ALB CYP2E1 DLAT F2
4 renal/urinary system MP:0005367 9.28 ADIPOQ ALB FAH GGT1 INS PKD1

Drugs & Therapeutics for Liver Disease

Drugs for Liver Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1073)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
2
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
3
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
4
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
5 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
6
Dalteparin Approved Phase 4 9005-49-6
7
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
8
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
9
Azithromycin Approved Phase 4 83905-01-5 55185 447043
10
Liraglutide Approved Phase 4 204656-20-2 44147092
11
Nitazoxanide Approved, Investigational, Vet_approved Phase 4 55981-09-4 41684
12
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
13
Clavulanate Approved, Vet_approved Phase 4 58001-44-8 5280980
14
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
15
Vancomycin Approved Phase 4 1404-90-6 441141 14969
16
Acamprosate Approved, Investigational Phase 4 77337-76-9 71158
17
Insulin lispro Approved Phase 4 133107-64-9
18
Imipenem Approved Phase 4 64221-86-9, 74431-23-5 104838
19
Insulin glulisine Approved Phase 4 207748-29-6
20
Lixisenatide Approved Phase 4 320367-13-3
21
Arsenic trioxide Approved, Investigational Phase 4 1327-53-3 518740
22
Atenolol Approved Phase 4 29122-68-7 2249
23
Nebivolol Approved, Investigational Phase 4 152520-56-4, 118457-14-0, 99200-09-6 71301
24
Cefotaxime Approved Phase 4 63527-52-6 456256 5742673
25
Cefoxitin Approved Phase 4 35607-66-0 441199
26
Caspofungin Approved Phase 4 162808-62-0, 179463-17-3 468682 2826718
27
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
28
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
29
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
30
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7 40400 644073
31
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
32
Ethanolamine oleate Approved Phase 4 2272-11-9
33
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
34
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030 46835353
35
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
36
Pravastatin Approved Phase 4 81093-37-0 54687
37
Iron Approved, Experimental Phase 4 7439-89-6, 15438-31-0 23925 27284
38
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
39
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
40
Rifampicin Approved Phase 4 13292-46-1 5458213 5381226
41
Baclofen Approved Phase 4 1134-47-0 2284
42
Anidulafungin Approved, Investigational Phase 4 166663-25-8 166548
43
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
44
Dobutamine Approved Phase 4 34368-04-2 36811
45
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
46
Adefovir dipivoxil Approved, Investigational Phase 4 142340-99-6 60871
47
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
48
Atropine Approved, Vet_approved Phase 4 5908-99-6, 51-55-8 174174
49
Deferiprone Approved Phase 4 30652-11-0 2972
50
Thiopental Approved, Vet_approved Phase 4 76-75-5 3000715

Interventional clinical trials:

(show top 50) (show all 3876)
# Name Status NCT ID Phase Drugs
1 Granulocyte Colony-stimulating Factor(G-CSF) in the Treatment of Hepatic Failure: a Prospective Randomized Controlled Clinical Study Unknown status NCT02331745 Phase 4 Granulocyte colony-stimulating factor;standard treatment
2 THE EFFECT OF DUAL TREATMENT WITH L-CARNITINE AND MAGNESIUM ON Patients With Non Alcoholic Fatty Liver Disease Unknown status NCT01956825 Phase 4
3 Randomised Controlled Study Comparing Use of Popofol Plus Fentanyl Versus Midazolam Plus Fentanyl as Sedation in Diagnostic Endoscopy in Patients With Advanced Liver Disease. Unknown status NCT03063866 Phase 4 Propofol;Midazolam;Fentanyl
4 Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Unknown status NCT00941642 Phase 4 Lovaza;placebo control
5 Intravenous-Morphine and Glucagon-Usage Enhanced MR Cholangiography Unknown status NCT00155376 Phase 4 morphine and glucagon
6 Evaluation of Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial Unknown status NCT02213224 Phase 4 Perindopril;Telmisartan;Amlodipine
7 Assessment of Coagulation Abnormalities in Acute on Chronic Liver Failure Patients Using Thromboelastography Unknown status NCT02757170 Phase 4
8 Branched-chain Amino Acid (BCAA) on Progression of Advanced Liver Disease (BRAVE): Korean Nation-wide Multicenter Retrospective and Prospective Observational Cohort Study Unknown status NCT02837302 Phase 4 Livact
9 An Randomized Open Label Trial on the Impact of 24 Weeks of Atorvastatin Therapy on Liver Fat Content and Abdominal Fat Content in Patients With Type 2 Diabetes Combined With High LDL-C and Non-alcoholic Fatty Liver Disease Unknown status NCT01720719 Phase 4 atorvastatin;Vitamin E
10 Influence of CYP3A5 Polymorphism on Liver Function Abnormality and the Trough Level Change After Conversion From Tacrolimus (Bid) to Advagraf® (qd) in Stable Liver Transplant Recipients Unknown status NCT02882113 Phase 4 Advagraf
11 A Randomized, Open Label, Phase IV, Multicenter Study for Efficacy and Safety of Lamivudine Versus Entecarvir Therapy in HBV-related Advanced Liver Disease Patients With High Viral Load and Normal or Slightly Elevated Transaminase Unknown status NCT00823550 Phase 4 Entecavir;Lamivudine
12 Effect of Probiotics on Gut-Liver Axis of Alcoholic Hepatitis Unknown status NCT02335632 Phase 4 Probiotics (Lacidofil®);Placebo
13 Entecavir for Patients With Decompensated HBV-Related Cirrhosis:a Prospective Randomized Controlled Trial Unknown status NCT00663182 Phase 4 Entecavir
14 Hepatic Function and Bile Acid in Preterm Infants Receiving Parenteral Lipids Emulsion Unknown status NCT01786759 Phase 4 ClinOleic;Intralipid
15 Development of an Imaging Biomarker for Hepatic Fibrosis Using Gadoxetate Disodium Unknown status NCT01783314 Phase 4
16 Safety of Acamprosate for Alcohol Dependence in the Elderly: An Open-Label Study Unknown status NCT00655967 Phase 4 Acamprosate (Campral);Acamprosate
17 Intravenous Paracetamol Versus Intravenous Dexketoprofen in Patients Presented With Dysmenorrhea in Emergency Department Unknown status NCT02373514 Phase 4 Paracetamol;Dexketoprofen
18 A Randomised Controlled Trial of Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis Unknown status NCT01950884 Phase 4 Ezetimibe
19 A Randomized Controlled Trial Comparing the Adductor Canal Catheter (ACC) and Intra-articular Catheter (IAC) Following Primary Total Knee Arthroplasty Unknown status NCT02497911 Phase 4 Ropivicaine;Bupivicaine
20 Magnesium Deficiency in Cirrhotic Patients Unknown status NCT01894867 Phase 4
21 The Orange-III Trial: Optimised Recovery With Movicol® Preoperatively Within an Enhanced Recovery Programme, a Randomised Controlled Trial Unknown status NCT01429779 Phase 4 Movicol
22 The Efficacy and Safety of Ursodeoxycholic Acid (UDCA) Added to the Dipeptidyl Peptidase-4 Inhibitor, Sitagliptin in People With Type 2 Diabetes and Chronic Liver Diseases Unknown status NCT01337440 Phase 4 UDCA;Sitagliptin
23 A Study Comparing Thymoglobulin to Tacrolimus in Liver Transplant and Impact on Renal Function Unknown status NCT00564538 Phase 4 anti-thymocyte globulin (rabbit);tacrolimus
24 Influence of Hepatic Steatosis on the Therapeutic Effect of Entecavir in Chronic Hepatitis B Patients-A Randomized, Double-Blinded, Controlled Trial Unknown status NCT01148576 Phase 4 entecavir;entecavir;essentiale + entecavir;Vitamin E + entecavir
25 Sustained Off-treatment Response After HBeAg Loss in HBeAg-Pos Chronic Hepatitis B Patients Treated With Nucleos(t)Ide Analogues Unknown status NCT01911156 Phase 4 Continue NA treatment;Discontinue NA Treatment
26 Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhosis: An Open Label, Randomized Controlled Trial of Lactulose, Probiotics and No-therapy Unknown status NCT01178372 Phase 4 Lactulose;Probiotics(VSL#3)
27 Treatment for Alcohol Dependence With Gabapentin: A Double Blind Placebo Controlled Randomized Clinical Trial Unknown status NCT02771925 Phase 4 Gabapentin 2g/day divided in two doses for 24 weeks;Placebo 2g/day divided in two doses for 24 weeks
28 A Double-Blinded Randomized Controlled Trial Comparing the Adductor Canal Catheter (ACC) and Local Infiltration of Analgesia (LIA) Following Primary Total Knee Arthroplasty Unknown status NCT02603900 Phase 4 ropivacaine;bupivacaine
29 Phase IV Study of Effectiveness of Interferon and Ribavirin Treatment in Thalassemia Major Patients With Chronic Viral Hepatitis C Unknown status NCT00887081 Phase 4 PEG-IFN alpha2a or PEG-IFN alpha2b and Ribavirin
30 Insulin Therapy in the Inpatient Management of Cirrhotic Patients With Type 2 Diabetes Unknown status NCT01143948 Phase 4 Glargine & Glulisine;Regular insulin;NPH & regular insulin
31 Efficacy and Safety of Certican® in Combination With Myfortic® in Adult Renal Allograft Recipients Following Calcineurin Inhibitor Withdrawal at Week 16 Compared to Patients Who Are Maintained on Tacrolimus and Myfortic® Unknown status NCT01399242 Phase 4 Certican
32 The Effect of the GLP-1 Receptor Agonists on Blood Levels of Lipoprotein (a) Unknown status NCT02501850 Phase 4 Liraglutide;metformin
33 A Randomized Comparison of Two Albumin Administration Schedules for Spontaneous Bacterial Peritonitis Unknown status NCT00761098 Phase 4 Standard Care;Experimental
34 Phase IV Study of the Efficacy of Entecavir in Patients With Chronic Hepatitis B Virus Infection and Persistently Normal Alanine Aminotransferase Unknown status NCT01833611 Phase 4 Entecavir;placebo
35 A Phase 4, Open-Label Study to Investigate the Efficacy and Safety of Tenofovir Disoproxil Fumarate (Viread(R)) in Preventing Hepatocellular Carcinoma Recurrence in Chronic Hepatitis B Virus Infected Patients With Low Viral Load at Baseline Treated With Radiofrequency Ablation or Resection Unknown status NCT02308319 Phase 4 Tenofovir disoproxil fumarate
36 An Efficacy and Safety Study Comparing Pegylated-Interferon and Ribavirin Plus Metformin to Pegylated-Interferon and Ribavirin in the Treatment of naïve Patients With Genotype 1 Chronic HCV Infection and Insulin Resistance Unknown status NCT00370617 Phase 4 metformin
37 The Effect of Empagliflozin on NAFLD in Asian Patients With Type 2 Diabetes Unknown status NCT02964715 Phase 4 Empagliflozin
38 the Safety and Effect in TB Patients With NAC Unknown status NCT02889757 Phase 4 Acteylcysteine
39 Treating HIV-infected Elite Controllers as a Model of HIV Remission Unknown status NCT01025427 Phase 4 Raltegravir, tenofovir/emtricitabine
40 Randomized Controlled Trial Comparing Effects of Sedation for Upper Gastrointestinal Endoscopy With Propofol Versus Midazolam on Psychometric Tests and Critical Flicker Frequency in Cirrhotics Unknown status NCT01356121 Phase 4 Propofol;Midazolam
41 RCT of Carvedilol vs Variceal Band Ligation in the Primary Prophylaxis of Oesophageal Variceal Haemorrhage Unknown status NCT01070641 Phase 4 Carvedilol
42 Treatment of Relapsed Acute Promyelocytic Leukemia With Arsenic Trioxide (Phase IV Study) Unknown status NCT00196768 Phase 4 Arsenic trioxide;Trisenox
43 Metformin for Weight Control in Adolescents Taking Atypical Antipsychotics- Double Blind Placebo Controlled Study Unknown status NCT00845936 Phase 4 Metformin
44 Banlangen Granules Anti-seasonal Influenza Study: a Randomized, Double Blind, Positive and Placebo Controlled,Clinical Study. Unknown status NCT02232945 Phase 4 placebo of oseltamivir phosphate;oseltamivir phosphate;Banlangen (Radix Isatidis) granules;placebo of Banlangen(Radix Isatidis) granules
45 Randomized Trial of Switch to Tenofovir Versus Continue Lamivudine/Adefovir Treatment in Lamivudine-resistance Chronic Hepatitis B Patients Who Have Undergone Lamivudine/Adefovir Add-on Treatment Unknown status NCT01491295 Phase 4 Tenofovir disoproxil fumarate;Lamivudine plus adefovir
46 the Efficacy and Safety of Indobufen and Low-dose Aspirin in Different Regimens of Antiplatelet Therapy Unknown status NCT03230851 Phase 4 aspirin 100mg/d therapy;aspirin 100mg/2d therapy;aspirin 100mg/3d therapy;aspirin 50mg bid therapy;aspirin 75mg/d therapy;aspirin 50mg/d therapy;indobufen 100mg bid therapy
47 Efficacy and Safety of a Hansenula-derived Pegylated Interferon α2a (Reiferon Retard®) in Treatment of Patients With Chronic Hepatitis C Virus Infection: A National Multi-center Phase IV Open Label Non-Randomized Trial Unknown status NCT01649245 Phase 4 Reiferon retard
48 Effect of Liraglutide on Fatty Liver Content Evaluated by Proton-spectroscopy (1H-spectroscopy) and Lipoprotein Kinetic, in Patients With Type 2 Diabetes Unknown status NCT02721888 Phase 4 Liraglutide;MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)
49 Telaprevir in Patients With Genotype 3 HCV: Pilot Clinical Study to Evaluate Efficacy and Predictability of Therapy in Patients Who Have Failed to Respond to Pegylated Interferon and Ribavirin Unknown status NCT02087111 Phase 4 Telaprevir;40 Kd Pegylated interferon alfa 2a;Ribavirin
50 Granulocyte Colony Stimulating Factor Plus N-Acetyl Cysteine In Severe Alcoholic Hepatitis Unknown status NCT02971306 Phase 4 standard medical therapy;G-CSF;n-Acetylcysteine

Search NIH Clinical Center for Liver Disease

Inferred drug relations via UMLS 71 / NDF-RT 50 :


alglucerase
imiglucerase
Medium chain triglycerides

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Liver Disease cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: liver diseases

Genetic Tests for Liver Disease

Genetic tests related to Liver Disease:

# Genetic test Affiliating Genes
1 Abnormality of the Liver 29
2 Hepatic Failure 29

Anatomical Context for Liver Disease

MalaCards organs/tissues related to Liver Disease:

40
Liver, Testes, Kidney, Bone, T Cells, Heart, Endothelial

Publications for Liver Disease

Articles related to Liver Disease:

(show top 50) (show all 49980)
# Title Authors PMID Year
1
Testing for Nonalcoholic Fatty Liver Disease. 61 42
31714988 2019
2
Preventive and Therapeutic Effect of Ganoderma (Lingzhi) on Liver Injury. 61 42
31777021 2019
3
The genetic variants in calcium signaling related genes influence anti-tuberculosis drug induced liver injury: A prospective study. 42
31689868 2019
4
Elevated hydroxyacylcarnitines in a carrier of LCHAD deficiency during acute liver disease of pregnancy - a common feature of the pregnancy complication? 54 61
20363656 2010
5
Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease. 54 61
20371660 2010
6
Beneficial effects of exercise training (treadmill) on insulin resistance and nonalcoholic fatty liver disease in high-fat fed C57BL/6 mice. 54 61
20490434 2010
7
Negative correlation between neuropeptide Y/agouti-related protein concentration and adiponectinemia in nonalcoholic fatty liver disease obese adolescents submitted to a long-term interdisciplinary therapy. 54 61
19942238 2010
8
The PXR is a drug target for chronic inflammatory liver disease. 54 61
20416375 2010
9
The spectrum of liver diseases related to ABCB4 gene mutations: pathophysiology and clinical aspects. 54 61
20422496 2010
10
Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis. 54 61
20102716 2010
11
The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease. 54 61
20415685 2010
12
Nonalcoholic fatty liver disease and HFE gene mutations: a Polish study. 54 61
20503453 2010
13
Hepatic expression of thyroid hormone-responsive spot 14 protein is regulated by constitutive androstane receptor (NR1I3). 54 61
20185760 2010
14
Effect of Xuezhikang Capsule on serum tumor necrosis factor-alpha and interleukin-6 in patients with nonalcoholic fatty liver disease and hyperlipidemia. 54 61
20473736 2010
15
[The value of MELD in the allocation of priority for liver transplantation candidates]. 54 61
19631411 2010
16
Is alanine aminotransferase level a surrogate biomarker of hepatic apoptosis in nonalcoholic fatty liver disease? 54 61
20406065 2010
17
Serum apoptotic caspase activity in chronic hepatitis C and nonalcoholic Fatty liver disease. 54 61
19881359 2010
18
Hepatic senescence marker protein-30 is involved in the progression of nonalcoholic fatty liver disease. 54 61
19946731 2010
19
Nuclear receptors, inflammation, and liver disease: insights for cholestatic and fatty liver diseases. 54 61
20200515 2010
20
Studies of gamma-glutamyl transferase in alpha-1 antitrypsin deficiency. 54 61
20397813 2010
21
The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance. 54 61
20093562 2010
22
Nonlinear distribution of adiponectin in patients with nonalcoholic fatty liver disease limits its use in linear regression analysis. 54 61
19770674 2010
23
Mechanisms linking obesity, chronic kidney disease, and fatty liver disease: the roles of fetuin-A, adiponectin, and AMPK. 54 61
20150538 2010
24
HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease. 54 61
19931264 2010
25
The new therapeutic frontier--nuclear receptors and the liver. 54 61
20133000 2010
26
Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. 54 61
20335584 2010
27
Natural anticoagulants can be useful predictors of severity in chronic liver disease. 54 61
20019598 2010
28
Macrophage migration inhibitory factor expression and MIF gene -173 G/C polymorphism in nonalcoholic fatty liver disease. 54 61
19829123 2010
29
Prevalence of genetic polymorphisms in the promoter region of the alpha-1 antitrypsin (SERPINA1) gene in chronic liver disease: a case control study. 54 61
20170533 2010
30
Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease. 54 61
20176643 2010
31
[Patomechanisms of hepatic steatosis]. 54 61
20159747 2010
32
Association of polymorphisms of glutamate-cystein ligase and microsomal triglyceride transfer protein genes in non-alcoholic fatty liver disease. 54 61
19817962 2010
33
[The roles of cyclooxygenase-2 and 5-lipoxygenase in liver disease]. 54 61
20196963 2010
34
Therapeutic effect of bezafibrate against biliary damage: a study of phospholipid secretion via the PPARalpha-MDR3 pathway. 54 61
20040336 2010
35
Differential diagnosis of liver diseases using serum biomarkers. 54 61
20414942 2010
36
The nuclear receptor PXR gene variants are associated with liver injury in nonalcoholic fatty liver disease. 54 61
19940802 2010
37
[Is venous thrombembolism during pregnancy an indication for routine assay of antithrombin activity and antithrombin supplementation?]. 54 61
20232702 2010
38
Comparison of modes of prothrombin time reporting in patients with advanced liver disease associated with viral hepatitis. 54 61
19330428 2010
39
Influence of amino-acid polymorphism in the core protein on progression of liver disease in patients infected with hepatitis C virus genotype 1b. 54 61
19950230 2010
40
Plasma interleukin-18/interleukin-18 binding protein ratio in Chinese with NAFLD. 54 61
20422882 2010
41
Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers. 54 61
19793164 2010
42
The role of cytokines in non-alcoholic fatty liver disease. 54 61
20460908 2010
43
Tumor necrosis factor-alpha accelerates apoptosis of steatotic hepatocytes from a murine model of non-alcoholic fatty liver disease. 54 61
20043871 2010
44
Animal models for hepatitis C and related liver disease. 54 61
20156300 2010
45
Apoptosis in immune-mediated liver diseases. 54 61
20460903 2010
46
Nonalcoholic fatty liver disease in primary aldosteronism: a pilot study. 54 61
19910932 2010
47
Variants in the UGT1A1 gene and the risk of pediatric nonalcoholic fatty liver disease. 54 61
19948621 2009
48
Systematic review: caspase-cleaved fragments of cytokeratin 18 - the promises and challenges of a biomarker for chronic liver disease. 54 61
19769633 2009
49
Impact of fish oil-based lipid emulsion on serum triglyceride, bilirubin, and albumin levels in children with parenteral nutrition-associated liver disease. 54 61
19687773 2009
50
[Fatty liver disease, insulin resistance and adiponectin in an obese pediatric population]. 54 61
19850541 2009

Variations for Liver Disease

ClinVar genetic disease variations for Liver Disease:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 MYOM1 NM_003803.4(MYOM1):c.3260G>A (p.Trp1087Ter)SNV Likely pathogenic 804425 18:3116372-3116372 18:3116374-3116374

Expression for Liver Disease

Search GEO for disease gene expression data for Liver Disease.

Pathways for Liver Disease

Pathways related to Liver Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1